# Alterome Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alterome-therapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.alterome.com
- Total disclosed funding: $231M
- Latest round: Series B (Apr 3, 2024)
- Investors on record: 11

## About

Based in California, US, and founded in 2019, Alterome Therapeutics, Inc. is a biopharmaceutical company developing alteration-specific targeted therapies for the treatment of cancer. Eric Murphy is the CEO of the company. In April 2024, Alterome Therapeutics, Inc. raised USD 132 million in a Series B funding led by Goldman Sachs Asset Management, with participation from Blue Owl Capital, Boxer Capital, Canaan Partners, Colt Ventures, Digitalis Ventures, Driehaus Capital Management LLC, Invus, OrbiMed Advisors, Nextech, and Vida Ventures.The series B funding values Alterome Therapeutics, Inc. at USD 342.65 million post-money.
 
The firm develops alteration-specific therapeutics to address high-value and validated oncogenic drivers, providing the healthcare industry with better therapies for the treatment of cancer.

The organization plans to use the January 2022 funding to advance the firm's precision oncology research efforts and pipeline, particularly those involving the creation of alteration-specific therapies.

## Funding rounds

- Series B, Apr 3, 2024, $132M — OrbiMed Advisors, Canaan Partners, Colt Ventures, Invus [DUP], Nextech, Goldman Sachs Asset Management, Driehaus Capital Management, Digitalis Ventures, Vida Ventures, Blue Owl, Boxer Capital
- Series A, Sep 30, 2022, $35M — OrbiMed Advisors, Colt Ventures, Nextech, Boxer Capital, Vida Ventures
- Series A, Dec 31, 2021, $64M — OrbiMed Advisors, Nextech, Boxer Capital, Vida Ventures

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- Nextech (https://capitalatlas.ai/funds/nextech) — Series A, Series B
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series A, Series B
- Vida Ventures (https://capitalatlas.ai/funds/vida-ventures) — Series A, Series B
- Colt Ventures (https://capitalatlas.ai/funds/colt-ventures) — Series A, Series B
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series B
- Invus [DUP] — Series B
- Goldman Sachs Asset Management (https://capitalatlas.ai/funds/goldman-sachs-asset-management) — Series B
- Driehaus Capital Management (https://capitalatlas.ai/funds/driehaus-capital-management) — Series B
- Digitalis Ventures (https://capitalatlas.ai/funds/digitalis-ventures) — Series B
- Blue Owl (https://capitalatlas.ai/funds/blue-owl) — Series B